BioPharmSignal logoBioPharmSignal

Biotech News

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines (RVMD)Revolution MedicinesEarnings

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation RASolute 302 data planned for submission to global regulatory authorities, including

Related news

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

FATEFate Therapeutics2026-05-13 12:30 EST

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

ERASErasca2026-05-11 20:01 EST

Erasca Reports First Quarter 2026 Business Updates and Financial Results

BMYBMYBristol-Myers Squibb Company2026-07-30 10:59 EST

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

View all latest news

Revolution Medicines

Revolution Medicines is a RAS-focused oncology company building a platform around RAS-addicted cancers and next-generation inhibitors.

Recent company news

RVMDRevolution Medicines2026-05-31 12:06 EST

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

RVMDRevolution Medicines2026-05-21 20:05 EST

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

RVMDRevolution Medicines2026-05-06 22:00 EST

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

RVMDRevolution Medicines2026-05-06 20:02 EST

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

RVMDRevolution Medicines2026-05-01 14:41 EST

Revolution Medicines Statement on FDA Expanded Access Authorization for Daraxonrasib in Patients with Previously Treated Metastatic Pancreatic Cancer

Stock data

Close
180.92 USD
Market cap
32.17B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States